Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific Antibody-Drug, Conjugate in Participants With Select Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill…
Locally Advanced (Unresectable) or Metastatic Solid Tumors
Estimated
~$10 – $8,750
NEOK Bio, Inc.NCT07612189
Phase 1
A Phase 1 Dose Escalation and Expansion Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific Antibody-Drug Conjugate, in Participants With Select, Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfil…
Locally Advanced (Unresectable) or Metastatic Solid Tumors
Estimated
~$10 – $8,750
NEOK Bio, Inc.NCT07612176